DAPT, a γ-secretase inhibitor, which reduces gamma-secretase in Notch1 signaling pathway was reported as a highly promising novel therapeutic drug candidate for ovarian cancer patient [21]. Here, NOTCH1 is linked to ovarian carcinoma.